As a glycoprotein, a high expression level of CD44 is associated with poor prognosis of cancer patients, including head and neck squamous cell carcinoma (HNSCC) [33], glioblastoma [34], and hepatocellular carcinoma [35]. This evidence concerns the gene CD44 and glioblastoma.